Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clindamycin
Drug ID BADD_D00483
Description Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris.[L11593] It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli.[A190621] Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.[A190657] Clindamycin is derived from, and has largely replaced, [lincomycin], a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from _Streptomyces lincolnensis_ found in a soil sample.[A190621]
Indications and Usage In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci.[L11599,L11602] Used topically, it is indicated for the treatment of acne vulgaris[L11593,L11611,L11605] and is available in combination with [benzoyl peroxide][L11584] or [tretinoin][L11590] for this purpose. Clindamycin is also indicated as a vaginal cream[L11596], suppository[L11608], or gel[L39416] for the treatment of bacterial vaginosis in non-pregnant females. Clindamycin is used for antimicrobial prophylaxis against _Viridans_ group streptococcal infections in susceptible patients undergoing oral, dental, or upper respiratory surgery, and may be used for prophylaxis against bacterial endocarditis in penicillin-allergic patients at high risk of these infections.[L11629]
Marketing Status approved; vet_approved
ATC Code D10AF01; G01AA10; J01FF01
DrugBank ID DB01190
KEGG ID D00277
MeSH ID D002981
PubChem ID 2786
TTD Drug ID D0R0ZL
NDC Product Code 67457-816; 71872-7168; 67457-817; 67457-815; 67457-814; 16781-462
UNII 3U02EL437C
Synonyms Clindamycin | Chlolincocin | 7-Chloro-7-deoxylincomycin | 7 Chloro 7 deoxylincomycin | Chlorlincocin | Dalacin C | Clindamycin Monohydrochloride | Monohydrochloride, Clindamycin | Clindamycin Monohydrochloride, Monohydrate | Monohydrate Clindamycin Monohydrochloride | Monohydrochloride, Monohydrate Clindamycin | Cleocin | Clindamycin Hydrochloride | Hydrochloride, Clindamycin
Chemical Information
Molecular Formula C18H33ClN2O5S
CAS Registry Number 18323-44-9
SMILES CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tenderness08.01.08.005--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tongue discolouration07.14.02.006--Not Available
Toothache07.09.06.001--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.0010.000385%
Vaginal discharge21.08.02.002--
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vasculitis24.12.04.027; 10.02.02.0060.000030%
Vertigo17.02.12.002; 04.04.01.003--
Vestibular disorder17.02.02.008; 04.04.02.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.0030.000233%
Vulvitis21.14.02.006; 11.01.10.007--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Vulvovaginal discomfort21.08.02.005--Not Available
Vulvovaginal disorder21.08.01.003--Not Available
Vulvovaginal dryness21.08.02.003--
Vulvovaginitis11.01.10.003; 21.14.02.005--Not Available
Vulvovaginitis trichomonal21.14.02.007; 11.06.05.001--Not Available
Wheezing22.03.01.009--
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.0050.000075%Not Available
Application site dryness12.07.01.011; 23.03.03.024; 08.02.01.011--Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages